<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000340933">
  <TermName>paricalcitol</TermName>
  <TermPronunciation>(PAYR-ih-KAL-sih-tol)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance that is being used to treat overactive parathyroid glands in patients with kidney failure. It is also being studied in the treatment of cancer. Paricalcitol belongs to the family of drugs called vitamin D analogs.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000711655" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;paricalcitol&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000711654" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;paricalcitol&quot;" language="es" id="_4"/>
  <SpanishTermName>paricalcitol</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para tratar las glándulas paratiroideas demasiado activas en los pacientes con insuficiencia renal. Asimismo, se está estudiándo para el tratamiento del cáncer. El paricalcitol pertenece al tipo de medicamentos llamados análogos de la vitamina D.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2003-10-25</DateFirstPublished>
</GlossaryTerm>
